Trial Profile
Randomised trial of 13-valent conjugated pneumococcal vaccine (PCV13) for patients with multiple myeloma (MM)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2018
Price :
$35
*
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- 20 Nov 2018 New trial record
- 07 Oct 2018 Results presented at the IDWeek 2018